Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Cash & Current Investments (2017 - 2025)

Entera Bio has reported Cash & Current Investments over the past 9 years, most recently at $14.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 71.86% year-over-year to $14.9 million, compared with a TTM value of $14.9 million through Dec 2025, up 71.86%, and an annual FY2025 reading of $14.9 million, up 71.86% over the prior year.
  • Cash & Current Investments came in at $14.9 million for Q4 2025, up from $8.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $27.4 million in Q3 2021 to a low of $6.9 million in Q3 2024.
  • Median Cash & Current Investments over the past 5 years was $11.7 million (2022), compared with a mean of $13.9 million.
  • The sharpest move saw Cash & Current Investments soared 287.59% in 2021, then tumbled 50.55% in 2022.
  • Over 5 years, Cash & Current Investments stood at $24.9 million in 2021, then tumbled by 50.55% to $12.3 million in 2022, then dropped by 10.48% to $11.0 million in 2023, then fell by 21.41% to $8.7 million in 2024, then soared by 71.86% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Cash & Current Investments are $14.9 million (Q4 2025), $8.6 million (Q3 2025), and $10.9 million (Q2 2025).